Cardiovascular Disease in Patients With Chronic Myeloid Leukemia: JACC: CardioOncology State-of-the-Art Review [0.03%]
慢性粒细胞白血病患者的心血管疾病：JACC心脏肿瘤学现状回顾
Nazanin Aghel,Jeffrey Howard Lipton
Nazanin Aghel
Cardiovascular (CV) disease and risk factors are notably prevalent among patients with chronic myeloid leukemia (CML). The introduction of BCR::ABL1 tyrosine kinase inhibitors has significantly transformed the treatment paradigm for CML. Ho...
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review [0.03%]
超越血栓：肌体增生性肿瘤患者的肺动脉高血压和心力衰竭：JACC心血管病学-肿瘤学最新进展综述
Orly Leiva,Olivia Liu,Anthony Kanelidis et al.
Orly Leiva et al.
Patients with myeloproliferative neoplasms (MPNs) are at increased risk for cardiovascular disease. Although thrombosis is a well-recognized complication, emerging evidence indicates that nonthrombotic conditions, including heart failure (H...
Cardiovascular Risk, Health Metrics, and Cancer Prediction: A Scoping Review [0.03%]
心血管风险、健康计量和癌症预测的综述研究
Gretell Henriquez-Santos,Ji-Eun Kim,Sant J Kumar et al.
Gretell Henriquez-Santos et al.
Background: Cardiovascular disease (CVD) and cancer are leading global causes of morbidity and mortality. Given the shared risk factors, it is plausible that CVD risk scores and cardiovascular health (CVH) metrics could p...
Bidirectional Interaction in Cardio-Oncology Toward Novel Therapeutic Strategies for Cardiovascular Diseases: JACC: CardioOncology Primer [0.03%]
心胸肿瘤学中的双向互动——心血管疾病新型治疗策略：JACC：心胸肿瘤学入门论文
Lama Awwad,Laris Achlaug,Sharon Aviram et al.
Lama Awwad et al.
Epigenetic Age Acceleration Mediates Treatment Effects on Cardiometabolic and Cardiovascular Risk in Childhood Cancer Survivors [0.03%]
儿童癌症幸存者中表观遗传年龄加速介导了治疗对代谢性和心血管风险的影响
Xiaoxi Meng,Tiffany Eulalio,Yoonji Kim et al.
Xiaoxi Meng et al.
Background: Childhood cancer survivors are at increased risk for epigenetic age acceleration (EAA) and subsequent morbidities-including cardiometabolic risk factors (CMRFs) and cardiovascular diseases-due to prior genotox...
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research [0.03%]
心血管肿瘤学和临床肿瘤学研究之间的脱节
Rachele Cagnazzo,Mario Stabile,Gabriele Zoppoli et al.
Rachele Cagnazzo et al.
IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer: JACC: CardioOncology Expert Panel [0.03%]
儿童癌症幸存者心脏功能紊乱后蒽环类和蒽酮类药物的心脏毒性的等效比率：JACC心血管肿瘤学专家共识意见书
Theodorus W Kouwenberg,Elvira C van Dalen,Renée L Mulder et al.
Theodorus W Kouwenberg et al.
Anthracycline and anthraquinone agents are major contributors to cancer therapy-related cardiac dysfunction in childhood cancer. However, evidence-based equivalence ratios for estimating individual risk have not been incorporated into inter...
Reply: Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? [0.03%]
关于怀疑淀粉样变性（转甲状腺素蛋白）心肌病患者的心脏生物标志物：哪个临界值？回复函
Laura De Michieli,Omar F AbouEzzeddine,Angela Dispenzieri et al.
Laura De Michieli et al.
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? [0.03%]
怀疑淀粉样变性（转甲状腺素蛋白）心肌病患者的 cardiac biomarker：cut-offs 值是多少？
Alberto Aimo,Vincenzo Castiglione,Giuseppe Vergaro et al.
Alberto Aimo et al.
Inflammation in Focus: Does Variation in C-Reactive Protein Predict Coronary Calcification After Breast Radiotherapy? [0.03%]
炎症反应与冠状动脉钙化的关系：乳腺放疗后C-反应蛋白的变异起预测作用吗？
Médéa Locquet,Gaëlle Jimenez,Jean Ferrières et al.
Médéa Locquet et al.